ACUITAS THERAPEUTICS

Acuitas Therapeutics Inc.

Non-Confidential Presentation
June 2026



© 2026 Acuitas. All rights reserved.

Overview



WHO WE ARE

Acuitas is a globally recognized biotechnology company specializing in the **development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP).**

Our LNP has enabled **three world firsts**: Onpattro®, Comirnaty®, and the first personalized CRISPR gene therapy.

WHO WE WORK WITH

- Cutting edge **pharmaceutical & biotechnology** companies
- Leading **academics in universities & institutes**
- **Foundations** & **NGOs**

HOW WE WORK

As a technology platform provider, we exclusively work in collaboration with partners.

We do not have our own drug development programs – **we are focused on supporting our partners to bring their drug products to patients.**

ACUITAS THERAPEUTICS

Applying Our LNP Technology

Gene Editing
Expression of a **genome editing** protein to modify gene expression.

Gene Modulation
Expression of an **epigenic editor** to modify gene expression **without changing the genetic code.**

Vaccines
Expression of viral or bacterial proteins to generate a protective **immune response.**

Expression of **tumour antigens** (including personalized cancer vaccines).

Antibody & Therapeutic Protein Delivery
Expression of **proteins including prophylactic** or **therapeutic antibodies** to treat current and emerging diseases.

In Vivo CAR-T
Expression of a Chimeric Antigen Receptor for **in vivo production of CAR-T cells** to treat cancer and autoimmune disease.

ACUITAS THERAPEUTICS

Our Partners' Success

Products in Clinic



21 in Phase 1

4 in Phase 2

2 in Phase 3

Clinical Firsts

First Clinically Approved **RNA interference-based Medicine**

First Clinically Approved **mRNA Vaccine**

First **LNP enabled personalized CRISPR gene editing therapy**

May 2026: Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for Patients with Hepatitis B at EASL 2026

May 2026: Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose

May 2026: Ukko Announces First Participant Dosed in Phase 1/2a Clinical Study Evaluating UKK-0018 for Peanut Allergy Treatment

April 2026: CREATE Medicines Doses First Patient in Phase 1/2 Study of MT-304, a First-in-Class Multi-immune In Vivo CAR Therapy Targeting HER2-Positive Solid Tumors

December 2025: CREATE Medicines Doses First Patient in Frontline HCC Trial Evaluating MT-303, an In Vivo CAR Therapy, in Combination with Standard-of-Care Immunotherapy

November 2025: CREATE Medicines Announces Positive First-in-Human Results for MT-302

January 2026: nChroma Bio Announces First Patient Dosed in Phase 1/2 Clinical Trial of Epigenetic Silencer CRMA-1001 for Chronic Hepatitis B

January 2026: Centivax Initiates Phase 1 First-in-Human Clinical Trial of Universal Flu Vaccine

November 2025: Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

November 2025: Metagenomi Presents New Preclinical Data from MGX-001 Hemophilia A Program Supporting Advancement into Clinical Development

Aug 2025: Beam Therapeutics Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

July 2025: Arbor Biotechnologies Announces First Patient Dosed at Mayo Clinic in the redePHine Phase 1/2 Study of ABO-101, an Investigational Gene Editing Treatment for Primary Hyperoxaluria Type 1

Sept 2024: CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress

Our Approach to Innovation



ACUITAS THERAPEUTICS

Our Approach to Innovation



LEGEND cGMP ready + in clinic

ACUITAS THERAPEUTICS

Our Approach to Innovation

Top novel lipids have **equivalent or better potency at 0.3 mg/kg** compared to benchmark



ACUITAS THERAPEUTICS

Our Approach to Extrahepatic Targeting

TARGETED

Targeted delivery to immune cells and hematopoietic stem cells.

We use antibody mimetics called **Designed ankyrin repeat proteins (DARPins).**



tLNP with DARPin (Athebody™)

NON-TARGETED

Local delivery to the **eye, lung, and solid tumours.**



ACUITAS THERAPEUTICS

Complete Reduction of B Cells using CD8-Targeted LNP

- CD8-targeted LNP containing CD20 CAR mRNA at 0.2 mg/kg in NHP
- Up to **80% of CD8+ T cells** express CD20 CAR T cell receptor
- **Significant and sustained depletion** of peripheral B cells after treatment with CD8-targeted LNP containing CD20 CAR mRNA





**In vivo CAR-T work conducted in collaboration with an RNA therapeutics partner*

ACUITAS THERAPEUTICS

CD8-Targeted LNP Expressing CD20 CAR mRNA

Complete Reduction of B Cells in NHP Tissues at 0.2 mg/kg











**In vivo CAR-T work conducted in collaboration with an RNA therapeutics partner*

ACUITAS THERAPEUTICS

Best-in-Class Multivalent & Cancer Vaccine Potency

MULTIVALENT VACCINES

Next Generation vaccine LNP show similar activity at **5-fold lower dose vs. ALC-315®.**



CANCER VACCINES

Acuitas LNP demonstrate **increased abundance & functionality** of antigen-specific CD8 T cells vs. clinical comparator (SM-102).



ACUITAS THERAPEUTICS

Simplified Manufacture via Pre-Formed Vesicles (PFV)

PFV enables a kit format (2 vials) where mRNA is loaded into empty LNP at point-of-care



BENEFITS

Refrigerated (2-8°C) (and potential for room temperature) long term **storage & distribution**

Flexible, small-scale manufacturing capability

Modular, flexible, platform approach that is **fast and cost effective**



For Vaccine Applications (i.e., IM)

PFV achieves equivalent potency to conventional LNP manufacturing methods



For Systemic Applications (i.e., IV)

ACUITAS THERAPEUTICS

Accelerating Clinical Entry



Our breadth and depth of capabilities enables end-to-end drug development support.

ACUITAS THERAPEUTICS

Why Acuitas?

1 Best-in-class and First-in-class

We have unparalleled technology with:

- **First-in-class and best-in-class** drug products commercialized, including Onpattro® and Comirnaty®.
- A broad and **comprehensive IP portfolio.**

2 Accelerated Clinical Entry

We understand the importance of early clinical entry.

We provide access to **cGMP-grade lipids.**

Our **expertise in tech transfer and product scale up** de-risks your development program, saving you time and money.

Our partners have initiated **33 clinical trials** in the last 3 years.

3 Unparalleled Scientific Leadership & Experience

Working with academic scientists and key opinion leaders we **publish regularly in the top scientific journals**.

Our team is at the cutting edge of scientific discovery.

ACUITAS THERAPEUTICS

Our Scientific Leadership

Mechanism of Action	nature	• Spatial profiling of gene editing by in situ sequencing in mice and macaques (2025)
	Cell	• Distinct components of nucleoside-modified messenger RNA vaccines cooperate to instruct efficient germinal center responses (2025)
	nature	• Molecular fate-mapping of serum antibody responses to repeat immunization (2023)
Therapeutic Areas	The New England Journal of Medicine	• Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease (2025)
	nature	• Treatment of a metabolic liver disease in mice with a transient prime editing approach (2025)
	nature	• A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels (2025)
	Cell	• Physiologically based modeling of LNP-mediated delivery of mRNA in the vascular system (2024)
Extra-hepatic Application	Cell	• Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke (2024)
	Advanced Healthcare Materials	• Exploring Mechanisms of Lipid Nanoparticle-Mucus Interactions in Healthy and Cystic Fibrosis Conditions (2024)
	Science	• In vivo modification of hematopoietic stem cells by targeted lipid nanoparticles delivering mRNA (2023)
	Science	• CAR T cells produced in vivo to treat cardiac injury (2022)
Vaccine Improvements	Science	• Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates (2025)
	Science	• An IL-12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses (2025)
	Science	• A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection (2024)
	Science Translational Medicine	• Computationally designed mRNA-launched protein nanoparticle immunogens as an integrated vaccine platform (2025)

For a current list of publications, please visit our website here.

ACUITAS THERAPEUTICS

How We Collaborate



An opportunity to evaluate our technology

A collaboration to optimize your clinical candidate and select the ideal LNP formulation.

A license to enable clinical trials and commercialization of your product.

*: Shipping costs may apply.

ACUITAS THERAPEUTICS

Let's Connect

bd@acuitastx.com
https://acuitastx.com/

ACUITAS THERAPEUTICS